Isomorphic Labs announced on November 19, 2026, a strategic research collaboration with MSD to discover small-molecule oncology drug candidates, combining its AI drug-design engine with selected proprietary datasets and discovery expertise from the pharmaceutical company. MSD is the trade name used by Merck & Co., Inc., outside the United States and Canada. The partners will work against an oncology target they describe as strategically important. The announcement concerns early discovery work…